Emerging evidence positions the cyclic GMP–AMP synthase (cGAS)–stimulator of interferon (IFN) genes (STING) pathway as a viable target in tumour immunotherapy, given its pivotal function in facilitating T lymphocytes.4, 5. The gene discussed is IFNA1; the disease is neoplasm.